Al Mousa Eyas, Al-Azzam Sayer, Araydah Mohammad, Karasneh Reema, Ghnaimat Mohammad, Al-Makhamreh Hanna, Al Khawaldeh Abdelkarim, Ali Abu Al-Samen Muneer, Haddad Jihad, Al Najjar Said, Alsalaheen Abbadi Hatem, Hammoudeh Ayman J
Jordanian Atherosclerosis and Hypertension Society, Amman 11942, Jordan.
Clinical Pharmacy Department, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.
J Clin Med. 2023 Jun 27;12(13):4312. doi: 10.3390/jcm12134312.
Atherosclerotic cardiovascular disease (ASCVD) is the primary contributor to global mortality rates, which significantly escalates healthcare expenditures. Risk factors for ASCVD (including dyslipidemia) frequently present in clusters rather than separately. Addressing these risk factors is crucial in the early initiation of a comprehensive management plan that involves both lifestyle modifications and pharmacotherapy to reduce the impact of ASCVD. A team of Jordanian professionals from various medical organizations and institutes took the initiative to create a set of guidelines for dyslipidemia screening and therapy. A detailed, comprehensive literature review was undertaken utilizing several databases and keywords. This consensus statement provides recommendations for dyslipidemia management in Jordanians on several issues including cardiovascular risk estimation, screening eligibility, risk categories, treatment goals, lifestyle changes, and statin and non-statin therapies. It is recommended that all Jordanian individuals aged 20 years old or older undergo lipid profile testing. This should be followed by determining the level of cardiovascular risk depending on the presence or absence of ASCVD and cardiovascular risk factors, eligibility for lipid-lowering therapy, and the target low-density cholesterol serum level to be achieved. In conclusion, prioritizing the management of dyslipidemia is of the utmost importance in improving public health and reducing the burden of cardiovascular diseases.
动脉粥样硬化性心血管疾病（ASCVD）是全球死亡率的主要促成因素，这显著增加了医疗保健支出。ASCVD的危险因素（包括血脂异常）常常成群出现而非单独存在。在早期启动一项综合管理计划（包括生活方式改变和药物治疗）以减轻ASCVD的影响方面，应对这些危险因素至关重要。一组来自约旦各医疗组织和机构的专业人员主动制定了一套血脂异常筛查和治疗指南。利用多个数据库和关键词进行了详细、全面的文献综述。本共识声明就约旦人血脂异常管理的几个问题提供了建议，包括心血管风险评估、筛查资格、风险类别、治疗目标、生活方式改变以及他汀类和非他汀类治疗。建议所有20岁及以上的约旦人进行血脂检测。随后应根据是否存在ASCVD和心血管危险因素、降脂治疗的资格以及要达到的目标低密度胆固醇血清水平来确定心血管风险水平。总之，优先管理血脂异常对于改善公众健康和减轻心血管疾病负担至关重要。
